Company intelligence / Profile preview

VETR

Portland, Oregon, United States

Ownership: Private
Development stage: Other

Overview

VETR is a veterinary biotechnology and technology company that provides a vertically integrated pet health ecosystem. The company integrates on-demand virtual veterinary consultations and AI-supported diagnostics with a scalable pharmaceutical distribution network. VETR is recognized for its ToltraMax (Toltrazuril) solution, an FDA-registered treatment for coccidiosis in companion animals, and its strategic acquisition of the Omeprazole.com domain from AstraZeneca to expand its animal health pharmaceutical portfolio. By bridging the gap between digital innovation and clinical veterinary medicine, VETR aims to improve treatment access and affordability for pet owners and professionals.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Small molecule
Industry: Veterinary

Partnerships

AstraZeneca

Beyond the preview

Go deeper on VETR.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VETR.

Explore the full profile